Corrigendum to: A Novel Cuproptosis-Related Gene Signature Predicts Prognosis in Papillary Thyroid Carcinoma Patients.

It has come to our notice that in the published version of this article [1], the study limitation section was missing. The revised section is provided below. The original article can be found online at https://benthamscience.com/public/article/%20142549 Details of the correction: Corrected: STUDY LIMITATIONS Our study has several limitations. Although the differential expression of CDKN2A was validated through bioinformatics analysis and qRT-PCR, further in vitro or in vivo experiments are needed to elucidate the molecular mechanisms by which CRGs contribute to PTC progression. Furthermore, prospective studies are necessary to assess the practical utility of the CRG signature. The publisher apologizes for any inconvenience caused.